• Brendon M Hart, Stephane M Ferrell, Mark W Motejunas, Lauren A Bonneval, Elyse M Cornett, Richard D Urman, and Alan D Kaye.
• Department of Anesthesiology, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA. Electronic address: bhart1@lsuhs.edu.
• Best Pract Res Clin Anaesthesiol. 2018 Jun 1; 32 (2): 165-178.

AbstractThere are several new anticoagulants on the market that will impact perioperative care, including the use of these anticoagulant drugs in the setting of regional anesthesia. The ideal pharmacological agent would prevent pathological thrombosis and allow for a normal response to vascular injury to limit bleeding. At present, all antithrombotic agents have increased bleeding risk as their main side effect. We describe the different categories of drugs, e.g., antiplatelet, anticoagulant, and thrombolytic, with particular emphasis on the new drugs that have been introduced into the market. These agents can be evaluated by a number of methods including low-, medium-, or high-risk procedures and guidelines and best practice standards that have been published regarding the amount of time to wait after stopping the medication and before performing a procedure, e.g., the American Society of Regional Anesthesia and Pain Medicine recommendations. The present investigation will also describe new reversal agents for anticoagulants and the implications of all these drugs for regional anesthesia.Copyright © 2018 Elsevier Ltd. All rights reserved.

20 keywords...

hide…